Catalent, Inc. (NYSE:CTLT) Receives $63.40 Consensus Price Target from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have earned a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation. The average 12 month price target among brokers that have issued a report on the stock in the last year is $63.40.

Separately, StockNews.com started coverage on shares of Catalent in a research report on Monday. They set a “hold” rating for the company.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Athos Capital Ltd bought a new stake in Catalent during the 3rd quarter worth $6,009,000. Oddo BHF Asset Management Sas bought a new stake in shares of Catalent during the third quarter worth about $8,480,000. State Street Corp raised its holdings in Catalent by 1.5% in the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after buying an additional 113,095 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Catalent in the 3rd quarter valued at approximately $1,131,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after buying an additional 14,373 shares during the period.

Catalent Stock Performance

Shares of NYSE CTLT opened at $63.48 on Tuesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The stock’s fifty day moving average price is $62.42 and its two-hundred day moving average price is $60.54. Catalent has a one year low of $41.15 and a one year high of $63.50.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.10) EPS. On average, equities analysts forecast that Catalent will post 0.78 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.